

2-Methacryloxytropone

**Kanji Kubo,^{a*} Eriko Fukeda,^a
Taisuke Matsumoto,^b Kazuhiko
Endo^a and Akira Mori^b**

^aSchool of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan, and ^bInstitute for Materials Chemistry and Engineering, Kyushu University, Kasuga-Koen, Kasuga, Fukuoka 816-8580, Japan

Correspondence e-mail:
kubo-k@hoku-iryo-u.ac.jp

Key indicators

Single-crystal X-ray study
 $T = 173\text{ K}$
 $\text{Mean } \sigma(\text{C-C}) = 0.002\text{ \AA}$
 $R \text{ factor} = 0.037$
 $wR \text{ factor} = 0.128$
Data-to-parameter ratio = 12.4


For details of how these key indicators were automatically derived from the article, see
<http://journals.iucr.org/e>.

Received 8 June 2006
Accepted 19 June 2006

The title compound, 7-oxo-1,3,5-cycloheptatrien-1-yl 2-methyl-2-propenoate, $C_{11}H_{10}O_3$, is known as an intermediate for the synthesis of biologically active polymers. In its crystal structure, the tropolone ring forms a dihedral angle of $69.76(2)^\circ$ with the ester plane, and intermolecular $\text{C}-\text{H}\cdots\pi$ and $\text{C}-\text{H}\cdots\text{O}$ interactions are observed.


Comment

Tropone and tropolones are important building blocks for constructing liquid crystals (Kubo, Mori *et al.*, 2005), organogelators (Kubo *et al.*, 2004), mercury(II) cation carriers (Mori *et al.*, 1996), chromo- and fluoroionophores (Yamamoto *et al.*, 2002; Yamamoto *et al.*, 2003), dyes (Kubo & Mori, 2001) and intermediates for drug synthesis (Vandecandelaere *et al.*, 1997). Tropone and tropolones are also known to have biological activity against bacteria, fungi and viruses (Trust & Bartlett, 1975). 2-Methacryloxytropone, in particular, has been employed as an intermediate for the synthesis of biologically active polymers (Cornell & Donaruma, 1965).



The crystal structures of both tropone and tropolone have been reported previously (Barrow *et al.*, 1973; Shimanouchi & Sasada, 1973). We have also reported the structures of 5-cyano- and 5-nitrotropolone (Kubo, Yamamoto & Mori, 2001), 2-butanoyloxy-5-nitrotropone (Kubo, Tsuruta & Mori, 2001), and 5-phenyltropone (Kubo, Matsumoto & Mori, 2005). We report here the crystal structure of 2-methacryloxytropone, (I), with the aim of contributing to a deeper understanding of the molecular structure, molecular assembly and biological activity of troponoids.

The seven-membered ring in (I) is nearly planar; the respective deviations of each atom from the least-squares plane defined by atoms C1–C7/O1/O2, are 0.0002 (13), 0.0584 (13), −0.0105 (13), −0.1031 (12), −0.0436 (13), 0.0959 (15), 0.1107 (13), −0.1134 (8) and 0.0424 (6) Å. The dihedral angle between the C1–C7/O1/O2 plane and the plane of the ester group (defined by atoms O2, O5 and C8) is $69.76(2)^\circ$, similar to that in 2-butanoyloxy-5-nitrotropone (71.8° ; Kubo, Tsuruta & Mori, 2001) and bis(5-hexyl-oxytropon-2-yl)-4,4-azobisisbenzoate (71.8° ; Kubo, Mori *et al.*, 2005). The C–C bond lengths of the seven-membered ring of (I) are different from those of tropolone (Shimanouchi &

**Figure 1**

The molecular structure of (I), showing displacement ellipsoids at the 50% probability level for non-H atoms.

**Figure 2**

The C–H···π interaction (indicated by a dotted line) in (I) [symmetry code: (i) $x, 1+y, z$].

Sasada, 1973) but similar to those of tropone (Barrow *et al.*, 1973).

Intermolecular C–H···π and C–H···O interactions are observed in the crystal structure (Table 2 and Fig. 2), with distances typical for these types of interactions: C–H···π 2.8–3.1 Å (Matsumoto *et al.*, 2002; Kubo, Matsumoto & Mori, 2005), C–H···O 2.5–2.7 Å (Kubo, Matsumoto & Mori, 2005; Takahashi *et al.*, 2006).

Experimental

Compound (I) was prepared by esterification of tropolone with methacryl chloride, according to a literature procedure (Cornell & Donaruma, 1965). Crystals of (I) were grown by slow evaporation of a hexane solution.

Crystal data

$C_{11}H_{10}O_3$	$Z = 4$
$M_r = 190.20$	$D_x = 1.349 \text{ Mg m}^{-3}$
Monoclinic, $P2_1/c$	$\text{Cu K}\alpha$ radiation
$a = 6.1152 (14) \text{ \AA}$	$\mu = 0.82 \text{ mm}^{-1}$
$b = 10.214 (2) \text{ \AA}$	$T = 173.1 \text{ K}$
$c = 15.113 (3) \text{ \AA}$	Block, colorless
$\beta = 97.263 (15)^\circ$	$0.30 \times 0.20 \times 0.15 \text{ mm}$
$V = 936.4 (3) \text{ \AA}^3$	

Data collection

Rigaku R-AXIS RAPID diffractometer	11901 measured reflections
φ scans	1702 independent reflections
Absorption correction: multi-scan (<i>ABSCOR</i> ; Higashi, 1995)	1441 reflections with $F^2 > 2\sigma(F^2)$
$T_{\min} = 0.643$, $T_{\max} = 0.885$	$R_{\text{int}} = 0.025$
	$\theta_{\max} = 68.2^\circ$

Refinement

Refinement on F^2	H-atom parameters constrained
$R[F^2 > 2\sigma(F^2)] = 0.037$	$w = 1/[0.0021F_o^2 + \sigma(F_o^2)]/(4F_o^2)$
$wR(F^2) = 0.128$	$(\Delta/\sigma)_{\text{max}} < 0.001$
$S = 1.01$	$\Delta\rho_{\text{max}} = 0.24 \text{ e \AA}^{-3}$
1702 reflections	$\Delta\rho_{\text{min}} = -0.23 \text{ e \AA}^{-3}$
137 parameters	

Table 1
Selected geometric parameters (Å, °).

O1–C1	1.2304 (19)	C3–C4	1.420 (2)
O2–C2	1.3962 (16)	C4–C5	1.355 (2)
C1–C2	1.470 (2)	C5–C6	1.422 (2)
C1–C7	1.4613 (18)	C6–C7	1.350 (2)
C2–C3	1.353 (2)		
C2–O2–C8–O3	14.13 (19)	O2–C8–C9–C10	-3.1 (2)
C2–O2–C8–C9	-167.73 (11)	O2–C8–C9–C11	176.49 (12)
C8–O2–C2–C1	65.47 (15)	O3–C8–C9–C10	174.94 (15)
C8–O2–C2–C3	-120.83 (13)	O3–C8–C9–C11	-5.4 (2)

Table 2
Hydrogen-bond geometry (Å, °).

$D\cdots H\cdots A$	$D\cdots H$	$H\cdots A$	$D\cdots A$	$D\cdots H\cdots A$
C6–H4···C10 ⁱ	0.95	2.84	3.702 (2)	152
C3–H1···O3 ⁱⁱ	0.95	2.51	3.240 (2)	134
C7–H5···O1 ⁱⁱⁱ	0.95	2.59	3.523 (2)	166
C10–H6···O2 ^{iv}	0.95	2.71	3.398 (2)	130
C10–H7···O1 ^v	0.95	2.49	3.325 (2)	147

Symmetry codes: (i) $x, y+1, z$; (ii) $x-1, y, z$; (iii) $-x+1, -y+1, -z+1$; (iv) $-x, -y, -z+1$; (v) $-x+1, -y, -z+1$.

H atoms bonded to C atoms were included in the refinement at calculated positions as riding atoms, with $C\cdots H = 0.95 \text{ \AA}$ and $U_{\text{iso}}(\text{H}) = 1.2U_{\text{eq}}(\text{C})$.

Data collection: *CrystalClear* (Rigaku, 1999); cell refinement: *CrystalClear*; data reduction: *CrystalStructure* (Rigaku/MSC, 2004); program(s) used to solve structure: *SIR97* (Altomare *et al.*, 1999); program(s) used to refine structure: *SHELXL97* (Sheldrick 1997); molecular graphics: *ORTEPIII* (Burnett & Johnson, 1996); software used to prepare material for publication: *CrystalStructure*.

References

- Altomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C., Guagliardi, A., Molterni, A. G. G., Polidori, G. & Spagna, R. (1999). *J. Appl. Cryst.* **32**, 115–119.
- Barrow, M. J., Mills, O. S. & Filippini, G. (1973). *J. Chem. Soc. Chem. Commun.* pp. 66–67.
- Burnett, M. N. & Johnson, C. K. (1996). *ORTEPIII*. Report ORNL-6895. Oak Ridge National Laboratory, Tennessee, USA.
- Cornell, R. J. & Donaruma, L. G. (1965). *J. Med. Chem.* **8**, 388–390.
- Higashi, T. (1995). *ABSCOR*. Rigaku Corporation, Tokyo, Japan.
- Kubo, K., Matsumoto, T. & Mori, A. (2005). *Acta Cryst.* **E61**, o2750–o2752.
- Kubo, K. & Mori, A. (2001). *Acta Cryst.* **E57**, o328–o329.
- Kubo, K., Mori, A., Ujiie, S. & Tschiesske, C. (2004). *J. Oleo Sci.* **53**, 575–579.
- Kubo, K., Mori, A., Ujiie, S. & Tschiesske, C. (2005). *J. Oleo Sci.* **54**, 179–183.
- Kubo, K., Tsuruta, T. & Mori, A. (2001). *Acta Cryst.* **E57**, o326–o327.
- Kubo, K., Yamamoto, E. & Mori, A. (2001). *Acta Cryst.* **C57**, 611–613.
- Matsumoto, A., Tanaka, T., Tsubouchi, T., Tashiro, K., Saragai, S. & Nakamoto, S. (2002). *J. Am. Chem. Soc.* **124**, 8891–8902.
- Mori, A., Kubo, K. & Takeshita, H. (1996). *Coord. Chem. Rev.* **148**, 71–96.
- Rigaku (1999). *CrystalClear*. Rigaku Corporation, Tokyo, Japan.
- Rigaku/MSC (2004). *CrystalStructure*. Version 3.7.0. Rigaku/MSC, The Woodlands, TX 77381-5209, USA.
- Sheldrick, G. M. (1997). *SHELXL97*. University of Göttingen, Germany.
- Shimanouchi, H. & Sasada, Y. (1973). *Acta Cryst.* **B29**, 81–90.
- Takahashi, H., Takechi, H., Kubo, K. & Matsumoto, T. (2006). *Acta Cryst.* **E62**, o2553–o2555.
- Trust, T. J. & Bartlett, K. H. (1975). *Antimicrob. Agents Chemother.* **8**, 381–383.
- Vandecandelaere, A., Martin, S. R. & Engelborghs, Y. (1997). *Biochem. J.* **323**, 189–196.
- Yamamoto, E., Kubo, K. & Mori, A. (2002). *Heterocycles*, **56**, 305–311.
- Yamamoto, E., Kubo, K. & Mori, A. (2003). *Bull. Chem. Soc. Jpn.* **76**, 627–634.